

Gemcitabine in combination with paclitaxel for advanced soft-tissue sarcomas

AMIR SONNENBLICK¹, FERAS ELEYAN¹, TAMAR PERETZ¹, INNA OSPOVAT²,
OFER MERIMSKY², TAMAR SELLA³, NILI PEYLAN-RAMU¹ and DANIELA KATZ¹

¹Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem 91120; ²Department of Oncology, The Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv 69978;

³Department of Radiology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel

Received December 31, 2014; Accepted February 20, 2015

DOI: 10.3892/mco.2015.545

Abstract. A limited number of chemotherapeutic agents have been found to be active against advanced soft-tissue sarcomas (STSs), particularly sarcomas that have progressed following doxorubicin treatment. The aim of this retrospective study was to determine the response to treatment with gemcitabine plus paclitaxel in patients with STSs. Data were collected on all patients with advanced non-resectable STS who were treated with a fixed dose 700 mg/m² gemcitabine in combination with 70 mg/m² paclitaxel on days 1 and 8 every 3 weeks. A total of 30 patients were included, with a median age of 56.4 years (range, 40-70 years). The gemcitabine/paclitaxel combination was well tolerated, with an overall response in 27% and a clinical benefit in 57% of the patients. The median progression-free survival was 6.1 months and the overall survival was 14.3 months. In conclusion, gemcitabine plus paclitaxel was found to be tolerable and effective in patients with advanced STSs.

Introduction

Soft-tissue sarcomas (STSs) are a heterogeneous family of malignancies originating from mesenchymal tissues. Patients who present with advanced-stage STS or develop disease recurrence following initial resection carry a poor prognosis, since the majority of chemotherapeutic agents have not achieved any survival benefit in this disease. However, ~30% of patients treated with doxorubicin achieve an objective response and the response rates may increase to 35-40% when doxorubicin is combined with ifosfamide (1,2). The combination of gemcitabine and docetaxel was also proven to be effective in advanced STS, particularly in patients with uterine leiomyosarcoma (LMS) (3). While single-agent gemcitabine exhibited

only modest activity, the overall response rates in phase II trials combining gemcitabine with docetaxel were in the range of 16-53% in this patient group (3-6). A higher efficacy with superior progression-free survival (PFS) and overall survival (OS) was also demonstrated with this combination in several comparative trials (3,7,8). Therefore, it became common practice in several sarcoma centers to initiate combination treatment, hypothesizing synergy between gemcitabine and docetaxel. Myelosuppression is the primary toxicity (grade 3-4 neutropenia in 17%, grade 3 anemia in 25% and severe thrombocytopenia in 10% of the patients) associated with this type of treatment (9). In addition, grade 3 non-hematological toxicities, including fatigue and myalgia, developed in 25% of the patients. Patients with advanced sarcoma are usually heavily pretreated, with limited bone marrow tolerance and impaired quality of life. Paclitaxel and docetaxel share the same mechanisms of action and were found to exhibit similar efficacies in certain types of cancer, such as breast and lung cancer. Paclitaxel has been proven to be more tolerable when administered weekly, according to studies on breast cancer (10-12). For example, in a prospective randomized trial assessing different schedules and regimens of paclitaxel vs. docetaxel in adjuvant therapy for breast cancer, 71% of those receiving docetaxel every 3 weeks developed grade 3 or 4 toxicities compared with 28% of those receiving weekly paclitaxel ($P=0.001$) (11). Therefore, we hypothesized that paclitaxel may substitute docetaxel in the combination with gemcitabine for STS and designed a modified weekly protocol of gemcitabine plus paclitaxel (G/P) to reduce toxicity and maintain the planned schedule. In this study, we report our single institution experience focusing on efficacy and tolerability of modified weekly G/P in 30 patients with advanced STS.

Patients and methods

Patients and chemotherapy treatment. The medical records of patients with advanced unresectable STS treated between 2002 and 2009 with the G/P protocol were retrospectively evaluated. The G/P protocol included fixed-dose gemcitabine 700 mg/m² intravenously (i.v.) over 90 min, followed by 70 mg/m² paclitaxel i.v. over 1 h on days 1 and 8 of every 3-week cycle. Our center (Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel) served as a

Correspondence to: Dr Daniela Katz, Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Kiryat Hadassah, POB 12000, Jerusalem 91120, Israel
E-mail: danielakatz@hadassah.org.il

Key words: gemcitabine, paclitaxel, soft-tissue sarcomas, stage 4

national referral center. The clinical evaluation upon each admission consisted of an updated medical history focusing on performance status, tolerability and toxicity and a complete blood count. Toxicities were recorded based on the written report of the admitting physician and graded according to the World Health Organization common toxicity criteria (13). The response to treatment was determined according to the Response Evaluation Criteria In Solid Tumors (RECIST) (14) based on computed tomography scan/magnetic resonance imaging scans performed after 2-3 courses of treatment. All the patients provided written informed consent regarding their participation in this study.

Results

Patient characteristics. A total of 30 patients were treated with G/P for advanced unresectable STS at the Sharett Institute of Oncology between 2002 and 2009. The patient characteristics are summarized in Table I. Half of the patients were treated for high-grade LMS and undifferentiated pleomorphic sarcoma. The vast majority of the patients (27/30) underwent resection of the primary tumor, with one-third (10/27) undergoing R0 resection, 11 received prior adjuvant chemotherapy and 17 patients underwent adjuvant radiotherapy. The majority of the patients (24/30) received a doxorubicin-based regimen prior to G/P. Only 3 patients received G/P as first-line therapy for advanced disease, whereas 21 received G/P as second-line and 6 as third-or further-line therapy. The most common metastatic site was the lung (24 patients) and 14 patients had ≥ 2 metastatic sites.

Treatment toxicities and response. The 30 patients in our cohort received a total of 190 cycles of G/P. There was no reported treatment-related mortality. The grade 3-4 hematological toxicities included neutropenia in 4 patients (with a single episode of culture-negative neutropenic fever) and anemia in 3 patients (12%). Non-hematological toxicity included grade 2 diarrhea (1 patient) and grade 3 sensory neuropathy (1 patient). Postponing treatment and dose reduction were required in 7 patients, which may explain the tolerability.

Clinical outcome. Of the 30 patients, 8 (27%) achieved a partial response and 10 (30%) experienced stable disease as best response, with an overall clinical benefit of 56%. None of the patients achieved a complete response. The median PFS and OS were 6.1 and 14.3 months, respectively. Of note, all the deceased patients succumbed to progressive disease. As noted above, there was no toxicity-related mortality.

Discussion

In this retrospective study, the combination of weekly gemcitabine and paclitaxel achieved a partial response rate of 27% and a disease stabilization rate of 30% in pretreated patients with advanced STS. The median PFS was 6.2 months and the OS reached 14.3 months. The regimen was well tolerated, without treatment-related mortality. The proportion of grade 3 and 4 hematological toxicities (~10%) in patients receiving this protocol was significantly lower compared with patients receiving docetaxel every 3 weeks (~46% incidence of neutropenia) (11).

Table I. Characteristics of the patients (n=30).

Characteristics	Values
Gender (male/female)	14/16
Median age at diagnosis, years (range)	56.4 (40-70)
Initial localization	
Extremities	14
Uterus	3
Retroperitoneum	3
Organs other than uterine corpus	10
Histology	
Leiomyosarcoma	10
Synovial sarcoma	1
Liposarcoma	3
Angiosarcoma	2
Epithelioid sarcoma	2
Rhabdomyosarcoma	1
UPS	5
Spindle cell sarcoma	3
Stromal sarcoma	2
Pleomorphic sarcoma	1
Initial FNCLCC grading	
I	1
II	1
III	15
Unknown	13
Previous treatment	
Initial surgery/no surgery	27/3
R0	10
R1	3
R2	3
Unknown	11
Previous adjuvant chemotherapy	11
Lines of chemotherapy prior to G/T	
None	3
1	21
2	5
≥ 3	1
Doxorubicin-based chemotherapy	24
Adjuvant radiation	17
Number of metastatic sites	
1	16
≥ 2	14
Site of metastasis	
Lung	24
Liver	5
Bone	6
Performance status	
0-1	24
2	4
3-4	2

UPS, undifferentiated pleomorphic sarcoma; FNCLCC, French Federation of Cancer Centers Sarcoma Group; G/T, gemcitabine in combination with paclitaxel.

To the best of our knowledge, this study is the first to evaluate the efficacy and tolerability of G/P in patients with STS. The combination of taxanes and gemcitabine is increasingly utilized in STS, as well as in bone sarcoma (7-9,15). Early-phase II studies evaluating fixed-dose rate infusion of gemcitabine 900 mg/m² administered over 90 min (days 1 and 8) in combination with docetaxel 100 mg/m² (day 8) every 21 days, achieved objective response rates of 17-36%, with a median time-to-progression of 5.6-6.2 months (4,7). The synergism between the two agents is of note. The addition of docetaxel to gemcitabine improved outcome compared with single-agent gemcitabine (4). These clinical results were also supported by cell culture data revealing that the sequencing of gemcitabine followed by docetaxel is significant, resulting in superior drug synergism compared with other sequencing (16). Our results with paclitaxel substituting docetaxel suggested equivalent efficacy with significantly reduced toxicity. Although gemcitabine and docetaxel are usually tolerated well when administered as front-line treatment with the support of granulocyte-colony stimulating factor (G-CSF), this combination becomes progressively less tolerable with more advanced lines of treatment. None of the patients in our retrospective cohort received prior G-CSF and, in general, the tendency was to avoid G-CSF and opt for a mild (usually 10%) dose reduction instead. With disease progression, pretreatment quality of life and tolerance to treatment become more pertinent to treatment selection.

Only a limited number of chemotherapeutic agents have been found to exhibit some efficacy as single agents in advanced sarcoma. Published studies on single-agent treatments, such as high-dose ifosfamide or temozolamide, reported a limited efficacy (17,18). Trabectedin, which has been approved in Europe for second- or further-line treatment of advanced STS, achieved response rates of ≤10%, with significant clinical benefit almost exclusively in LMS and liposarcoma patients (19). Trabectedin lacks cumulative toxicity; however, the first 2-3 cycles may be associated with significant hepatic and hematological toxicity. Pazopanib, a small molecule with vascular endothelial growth factor inhibitory characteristics, may be a viable treatment option for patients with metastatic non-adipocytic STS following chemotherapy. Although tolerance may be improved with dose reductions, pazopanib treatment was shown to stabilize disease in the vast majority of patients, with a limited number of detected responses when measured by RECIST (20).

Patients with STS who have previously received standard chemotherapy, including doxorubicin, ifosfamide, pazopanib, cyclophosphamide and dacarbazine, are faced with a limited number of therapeutic options. Therefore, it is crucial to establish an effective, tolerable protocol for heavily pretreated STS patients, which will control the symptoms and prolong PFS.

There were certain limitations to our study, mainly due to its retrospective design, the limited number of included patients with various histological diagnoses and the potential patient selection bias. In addition, the timing of imaging evaluations was not uniform in our patient population. However, despite these limitations, to the best of our knowledge, this is the first study to describe the efficacy and tolerability of paclitaxel as a substitute to docetaxel in the combination with gemcitabine for the treatment of patients with STS. Our study demonstrated that the combination of gemcitabine and paclitaxel is a tolerable and effective regimen in patients with advanced STSs,

particularly after doxorubicin-based regimens. However, these results require confirmation and validation in larger prospective studies.

References

1. Patel SR, Vadhan-Raj S, Burgess MA, Plager C, Papadopolous N, Jenkins J and Benjamin RS: Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. *Am J Clin Oncol* 21: 317-321, 1998.
2. Lorigan P, Verweij J, Papai Z, *et al*: European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study: Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. *J Clin Oncol* 25: 3144-3150, 2007.
3. Pautier P, Floquet A, Penel N, *et al*: Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). *Oncologist* 17: 1213-1220, 2012.
4. Maki RG, Wathen JK, Patel SR, *et al*: Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 (corrected). *J Clin Oncol* 25: 2755-2763, 2007.
5. Merimsky O, Meller I, Flusser G, Kollender Y, Issakov J, Weil-Ben-Arush M, Fenig E, Neuman G, Sapir D, Ariad S, *et al*: Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. *Cancer Chemother Pharmacol* 45: 177-181, 2000.
6. Svancárová L, Blay JY, Judson IR, *et al*: Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. *Eur J Cancer* 38: 556-559, 2002.
7. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R and Spriggs DR: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. *J Clin Oncol* 20: 2824-2831, 2002.
8. Hensley ML: Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas. *Curr Opin Oncol* 22: 356-361, 2010.
9. Hensley ML, Blessing JA, Mannel R and Rose PG: Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. *Gynecol Oncol* 109: 329-334, 2008.
10. Wist EA, Sommer HH, Ostenstad B, Risberg T and Fjaestad K: Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer. *Acta Oncol* 43: 11-14, 2004.
11. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC and Davidson NE: Weekly paclitaxel in the adjuvant treatment of breast cancer. *N Engl J Med* 358: 1663-1671, 2008.
12. Kellokumpu-Lehtinen P, Tuunanen T, Asola R, *et al*: Weekly paclitaxel - an effective treatment for advanced breast cancer. *Anticancer Res* 33: 2623-2627, 2013.
13. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. *Semin Radiat Oncol* 13: 176-181, 2003.
14. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 45: 228-247, 2009.
15. Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W and Daw NC: Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. *Cancer* 113: 419-425, 2008.
16. Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, Lee JS, Couwlier C, Palazzolo K and Baker LH: Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. *J Clin Oncol* 22: 1706-1712, 2004.

17. Sutton GP, Blessing JA, DeMars LR, Moore D, Burke TW and Grendys EC: A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. *Gynecol Oncol* 63: 25-27, 1996.
18. Talbot SM, Keohan ML, Hesdorffer M, Orrico R, Bagiella E, Troxel AB and Taub RN: A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. *Cancer* 98: 1942-1946, 2003.
19. Sanfilippo R, Grosso F, Jones RL, Banerjee S, Pilotti S, D'Incalci M, Dei Tos AP, Raspagliesi F, Judson I and Casali PG: Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. *Gynecol Oncol* 123: 553-556, 2011.
20. van der Graaf WT, Blay JY, Chawla SP, *et al*; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 379: 1879-1886, 2012.